

**PERSONAL INFORMATION****Erika Martinelli**

📍 University of Campania “Luigi Vanvitelli”,  
Department of Precision Medicine, Division of Medical Oncology  
Via Sergio Pansini, 5  
80131 Napoli

☎ 0815666628 3391128973

✉ [erika.martinelli@unicampania.it](mailto:erika.martinelli@unicampania.it)

🌐 <https://www.medicinasperimentale.unicampania.it/dipartimento/docenti?MATRICOLA=700833>

Sex F | *Date of birth* 05/03/1975 | *Nationality* Italian

Enterprise	University	EPR
<input type="checkbox"/> Management Level	<input type="checkbox"/> Full professor	<input type="checkbox"/> Research Director and 1st level Technologist / First Researcher and 2nd level Technologist / Principal Investigator
<input type="checkbox"/> Mid-Management Level	<input checked="" type="checkbox"/> Associate Professor	<input type="checkbox"/> Level III Researcher and Technologist
<input type="checkbox"/> Employee / worker level	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator

**WORK EXPERIENCE**

December 2018-ongoing	Associate Professor in Medical Oncology and MD at Medical Oncology Unit, Department of Precision Medicine, Università degli Studi della Campania “L. Vanvitelli “.
2013- 2018	Assistant Professor in Medical Oncology at Medical Oncology Unit, Department of Precision Medicine, Università degli Studi della Campania “L. Vanvitelli “.
2012- 2013	Research Fellow of Molecular Oncology, Università degli Studi della Campania “L. Vanvitelli “.
2008- 2012	Post-hoc, laboratory of Molecular Oncology, Università degli Studi della Campania “L. Vanvitelli “.
2003-2005	Research fellow Oncology Department, University Hospital Vall d’Hebron. Barcelona, Spain
2018- present	Subject Editor of Gastrointestinal Guidelines of ESMO (European Society of Medical Oncology)
2017- present	Editor of the Italian guidelines for colorectal cancer of AIOM (Italian Society of Medical Oncology)

**EDUCATION AND TRAINING**

2004-2008	PhD degree in “Medical Oncology” cum laude Second University of Naples- Tutor: Prof. Fortunato Ciardiello
2001 – 2004	Residency in Medical Oncology (50/50 cum laude) Second University of Naples
1994 – 2000	Degree in Medicine (110/110 cum laude), Second University of Naples

**WORK ACTIVITIES**

<b>Awards</b>	December 2021 winner of research award (III award Raffaele di Robbio) Associazione Angela Serra 2003-2014 Winner of ESMO research fellow Oncology Department, University Hospital Vall d’Hebron. Barcelona, Spain November 2010: National Award “Anna Maria Lo Sapio” research in Oncology
---------------	--

September 2009: "ECCO/EJC Young Investigator's Poster Award".

**Editorial activity**

Member of editorial board of ESMO OPEN, PeerJ; guest editor for ETAT.

**Invited presentations**

- Oral presentation . ESMO Congress "Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as rechallenge strategy: the phase II CAVE (Cetuximab-AVELumab) mCRC study". 19 September 2020.
- ESMO advanced course on CRC.Treatment for mCRC RAS WT in first line. 18 December 2021.
- Highlight on CRC. ESMO Congress . 21 September 2021.
- Poster Discussant on non-colorectal cancer tumor. World Congress on Gastrointestinal Cancer , 4 July 2020, Barcellona .
- "Cancro del colon-retto: highlights". News in GI oncology 2020, AIOM, 15 February 2020. Vicenza.
- "Precision medicine in the management of advanced Colorectal cancer." 4 May 2019, Taipei, Taiwan, 4.
- "Session XII: Presentation of Selected Abstract: Emerging New or Combination Drugs in GI Cancer."
- World Congress Gastrointestinal Cancer. 5 July 2019, Barcellona, Spain
- "What to expect from a mentor when talking about research?". National Congress (SEOM 2019), - Pamplona, Spain 22 October 2019.
- Therapeutic sequencing in metastatic colorectal cancer. 27 i TTD, Malaga, Spain 18 December 2019.
- "Colorectal cancer". ESMO course for medical students, Valencia , Spagna ,18 Luglio 2019.
- "How to find a good mentor in Europe". World Congress on Gastrointestinal Cancer (WCGIC), 22 June 2018, Barcellona.
- "Highlights of posters at ESMO GI on non-CRC". Highlights of posters at ESMO GI on non-CRC, 21 June 2018, Barcellona, Spagna.
- "Workshop o liquid biopsy". 18 October 2018, Barcellona, Spagna.
- "Gastric cancer". ESMO course for medical students , Valencia , Spagna ,17 Luglio 2018.
- "Therapy challenge in mcr: right vs left?pro". 19° National Congress GOIM, 19 June 2017, Napoli.
- "How to profit from opportunities in a competitive environment". ESMO Congress (European Society of Medical Oncology) 11 Settembre 2017, Madrid, Spagna.
- Italian National congress TUMORI DEL COLON "Revisione critica poster". XVII AIOM, 23 October 2015, Milano.
- "Optimizing therapeutic combinations of pimasertib, a selective MEK1/2 inhibitor, with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells". ESMO (European Society of Medical Oncology) – oral presentation , 29 Settembre 2012, Vienna.

**Grants**

- My First AIRC Grant 2016-2019 "The role of AXL in colorectal cancer: a new emerging target ", code 17778 (Principal Investigator).
- University Project VALERE n. Prot. n. 158444 "Genome tailored treatment for cure of metastatic gastric and colorectal cancer" (reaserch unit participant).
- Regional Campania projcet , "Identification, Characterization And Mining Of Colorectal Tumorigenesis: Cause, Prevention & Cure (iCURE)" (reaserch unit participant).
- MOTRICOLOR, Europea Projcet Horizon 2020, codie 635342, 2015-2020 (reaserch unit participant).
- Investigator Grant AIRC 2013: New molecules involved in resistance to EGFR and MEK inhibitors: the role of Ephrin receptors (Eph). Code 14800, (reaserch unit participant).
- Investigator Grant AIRC 2010: "Use of MEK inhibitors to overcome primary and acquired resistance to anti-EGFR therapies", code 10630 (reaserch unit participant).
- PRIN 2010-2011 " Ottimizzazione dei trattamenti personalizzati con le terapie con farmaci a bersaglio molecolare nel cancro del colon retto", code 2010F84SL7 (reaserch unit participant).

## ADDITIONAL INFORMATION

### Publications

170 publications in peer-review journals  
H index: 44 (Scopus ID 7005920149)

#### **Relevant publications:**

- Ciardiello D., Famiglietti V., Napolitano S., Esposito L., Normanno N., Avallone A., Latiano T., Maiello E., Pietrantonio F., Cremolini C., Santabarbara G., Pinto C., Troiani T., Martinelli E., Ciardiello F., Martini G. (2021). Skin toxicity as predictor of survival in refractory patients with ras wild-type metastatic colorectal cancer treated with cetuximab and avelumab (Cave) as rechallenge strategy. *CANCERS*, vol. 13, ISSN: 2072-6694, doi: 10.3390/cancers13225715.
- Ciardiello, Davide, Blauensteiner, Bernadette, Matrone, Nunzia, Belli, Valentina, Mohr, Thomas, Vitiello, Pietro Paolo, Martini, Giulia, Poliero, Luca, Cardone, Claudia, Napolitano, Stefania... (2021). Dual inhibition of TGF $\beta$  and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. *MEDICAL ONCOLOGY*, vol. 38, ISSN: 1357-0560, doi: 10.1007/s12032-021-01464-3
- Martinelli E., Martini G., Famiglietti V., Troiani T., Napolitano S., Pietrantonio F., Ciardiello D., Terminiello M., Borrelli C., Vitiello P. P., De Braud F., Morano F., Avallone A., Normanno N., Nappi A., Maiello E., Latiano T., Falcone A., Cremolini C., Rossini D... (2021). Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. *JAMA ONCOLOGY*, vol. 7, ISSN: 2374-2437, doi 10.1001/jamaoncol.2021.2915
- Rao S., Guren M. G., Khan K., Brown G., Renehan A. G., Steigen S. E., Deutsch E., Martinelli E., Arnold D. (2021). Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *ANNALS OF ONCOLOGY*, vol. 32, p. 1087-1100, ISSN: 0923-7534, doi: 10.1016/j.annonc.2021.06.015 - - Vitiello P. P., Martini G., Mele L., Giunta E. F., De Falco V., Ciardiello D., Belli V., Cardone C., Matrone N., Poliero L., Tirino V., Napolitano S., Della Corte C., Selvaggi F., Papaccio G., Troiani T., Morgillo F., Desiderio V., Ciardiello F., Martinelli E. (2021). Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. *JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH*, vol. 40, ISSN: 1756-9966, doi: 10.1186/s13046-020-01811-8 .
- Zaniboni A., Barone C. A., Banzi M. C., Bergamo F., Blasi L., Bordonaro R., Bartolomeo M. D., Costanzo F. D., Frassinetti G. L., Garufi C., Giuliani F., Latiano T. P., Martinelli E., Personeni N., Racca P., Tamburini E., Tonini G., Besse M. G., Spione M., Falcone A. (2021). Italian results of the PRECONNECT study: Safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer. *FUTURE ONCOLOGY*, vol. 17, p. 2315-2324, 1479-6694, doi: 10.2217/fon-2020-1278.
- Cardone C., Blauensteiner B., Moreno-Viedma V., Martini G., Simeon V., Vitiello P. P., Ciardiello D., Belli V., Matrone N., Troiani T., Morgillo F., Zito Marino F., Dentice M., Nappi A., Boccaccino A., Antoniotti C., Cremolini C., Pietrantonio F., Prager G. W., Normanno N... (2020). AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. *EUROPEAN JOURNAL OF CANCER*, vol. 138, p. 1-10, ISSN: 0959-8049, doi: 10.1016/j.ejca.2020.07.010
- Martini, Giulia, Cardone, Claudia, Vitiello, Pietro Paolo, Belli, Valentina, Napolitano, Stefania, Troiani, Teresa, Ciardiello, Davide, Della Corte, Carminia Maria, Morgillo, Floriana, Matrone, Nunzia... (2019). EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer. *MOLECULAR CANCER THERAPEUTICS*, ISSN: 1535-7163, doi: 10.1158/1535-7163.MCT-18-0539 .
- Stjepanovic N., Moreira L., Carneiro F., Balaguer F., Cervantes A., Balmana J., Martinelli E. (2019). Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *ANNALS OF ONCOLOGY*, vol. 30, p. 1558-1571, ISSN: 0923-7534, doi: 10.1093/annonc/mdz233.
- Van Cutsem E., Martinelli E., Cascinu S., Sobrero A., Banzi M., Seitz J. -F., Barone C., Ychou M., Peeters M., Brenner B., Hofheinz R. D., Maiello E., Andre T., Spallanzani A., Garcia-Carbonero R., Arriaga Y. E., Verma U., Grothey A., Kappeler C., Miriyala A... (2019). Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard

Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. *THE ONCOLOGIST*, vol. 24, p. 185-192, ISSN: 1083-7159, doi: 10.1634/theoncologist.2018-0072.

- Vitiello P. P., De Falco V., Giunta E. F., Ciardiello D., Cardone C., Vitale P., Zanaletti N., Borrelli C., Poliero L., Terminiello M., Arrichiello G., CAPUTO, Vincenzo, Famiglietti V., Iacono V. M., Marrone F., Di Liello A., Martini G., Napolitano S., Caraglia M....(2019). Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience. *CANCERS*, vol. 11, ISSN: 2072-6694, doi: 10.3390/cancers11101504.

- Vitiello, Pietro Paolo, Cardone, Claudia, Martini, Giulia, Ciardiello, Davide, Belli, Valentina, Matrone, Nunzia, Barra, Giusi, Napolitano, Stefania, Della Corte, Carmina, Turano, Mimmo...(2019). Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. *JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH*, vol. 38, ISSN: 1756-9966, doi: 10.1186/s13046-019-1035-0.

- Martinelli, Erika, Troiani, Teresa, Sforza, Vincenzo, Martini, Giulia, Cardone, Claudia, Vitiello, Pietro Paolo, Ciardiello, Davide, Rachiglio, Anna Maria, Normanno, Nicola, Sartore-Bianchi, Andrea...(2018). Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. *ESMO OPEN*, vol. 3, ISSN: 2059-7029, doi: 10.1136/esmoopen-2017-000299.

- Normanno, N., Esposito Abate, R., Lambiase, M., Forgione, L., Cardone, C., Iannaccone, A., Sacco, A., Rachiglio, A. M., Martinelli, E., Rizzi, D....(2018). RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. *ANNALS OF ONCOLOGY*, vol. 29, p. 112-118, ISSN: 0923-7534, doi: 10.1093/annonc/mdx417.

-Vogel A., Cervantes A., Chau I., Daniele B., Llovet J., Meyer T., Nault J. -C., Neumann U., Ricke J., Sangro B., Schirmacher P., Verslype C., Zech C. J., Arnold D., Martinelli E. (2018). Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *ANNALS OF ONCOLOGY*, vol. 29, p. iv238-iv255, ISSN: 0923-7534, doi: 10.1093/annonc/mdy308.

- Martinelli, Erika, Sforza, Vincenzo, Cardone, Claudia, Capasso, Anna, Nappi, Anna, Martini, Giulia, Napolitano, Stefania, Rachiglio, Anna Maria, Normanno, Nicola, Cappabianca, Salvatore...(2017). Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. *ESMO OPEN*, vol. 2, ISSN: 2059-7029, doi: 10.1136/esmoopen-2017-000177.

- Martinelli, E, Cardone, C, Troiani, T, Normanno, N, Pisconti, S, Sforza, V, Bordonaro, A R, Rachiglio, A M, Lambiase, M, Latiano, T P...(2016). Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. *ESMO OPEN*, vol. 1, ISSN: 2059-7029, doi: 10.1136/esmoopen-2016-000086.

- Sartore Bianchi, A, Trusolino, L, Martino, C, Bencardino, K, Lonardi, S, Bergamo, F, Zagonel, V, Leone, F, Depetris, I, MARTINELLI, Erika...(2016). Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. *THE LANCET ONCOLOGY*, vol. 17, p. 738-746, ISSN: 1470-2045, doi: 10.1016/S1470-2045(16)00150-9.

-MARTINELLI, Erika, Martini G, Cardone C, TROIANI, Teresa, Liguori G, Vitagliano D, Napolitano S, MORGILLO, Floriana, RINALDI, Barbara, Melillo RM, Liotti F, Nappi A, Bianco R, BERRINO, Liberato, Ciuffreda LP...(2015).AXL is an oncotarget in human colorectal cancer. *ONCOTARGET*, vol. 29, p. 23281-23296, ISSN: 1949-2553, doi: 10.18632/oncotarget.3962.

-TROIANI, Teresa, Napolitano S, Vitagliano D, MORGILLO, Floriana, Capasso A, Sforza V, Nappi A, Ciardiello D, CIARDIELLO, Fortunato, MARTINELLI, Erika (2014). Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition.. *CLINICAL CANCER RESEARCH*, ISSN: 1078-0432.

**Scientific background and coherence with proposed project**

My research area of interest on experimental cancer therapeutics is active since more than 10 years, with a specific expertise in CRC. It includes the development of new targeted agents against growth factors in a preclinical and

early clinical studies mainly in cancer. In particular defining the possible biological markers of intrinsic or acquired resistance to treatments.  
Referring to the project specifically that aims to identify new mechanism of “born to be good or born to be bad cancers” , it fits perfectly in my reaserch area of interest with a link between metabolic and immune studies.

According to law 679/2016 of the Regulation of the European Parliament of 27th April 2016, I hereby express my consent to process and use my data provided in this CV.

**Date**

27 April 2022

**Signature**

A handwritten signature in black ink, appearing to read "E. Mousa", written in a cursive style.